Inhibition of TOP2A expression results in altered signaling: in the context of pancreatic cancer, TOP2A overexpression activates the β-catenin pathway [10], while TOP2A downregulation inhibits extracellular signal-regulated kinase (ERK) and AKT activity in colon cancer [11]. Here, TOP2A is linked to familial pancreatic carcinoma.